Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
New new contracts, summarized for you
No login, no app to check — it comes to you
See who's moving and how much in your market
Arrowhead Pharma's Shares Price Target Cut After Signing Strategic Partnership with Sarepta Therapeutics
Contract Type
partnership
Description
Arrowhead Pharma has announced a significant strategic partnership with Sarepta Therapeutics, involving various TRiM programs. The collaboration includes a $500 million upfront cash payment to Arrowhead, a $325 million equity investment, and an additional $250 million to be paid over the next five years, along with potential milestones that could reach up to $10 billion and low double-digit royalties on future sales. This partnership is estimated to bolster Arrowhead's pro forma cash to $1.5 billion, sustaining its operations well into 2028.